160 related articles for article (PubMed ID: 9058592)
1. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation.
Cioffi CL; Garay M; Johnston JF; McGraw K; Boggs RT; Hreniuk D; Monia BP
Mol Pharmacol; 1997 Mar; 51(3):383-9. PubMed ID: 9058592
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Mewani RR; Tian S; Li B; Danner MT; Carr TD; Lee S; Rahman A; Kasid UN; Jung M; Dritschilo A; Gokhale PC
Int J Mol Med; 2006 Mar; 17(3):457-63. PubMed ID: 16465392
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.
Bennett MR; Anglin S; McEwan JR; Jagoe R; Newby AC; Evan GI
J Clin Invest; 1994 Feb; 93(2):820-8. PubMed ID: 8113414
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of atrial natriuretic peptide (ANP) C receptor expression by antisense oligodeoxynucleotides in A10 vascular smooth-muscle cells is associated with attenuation of ANP-C-receptor-mediated inhibition of adenylyl cyclase.
Palaparti A; Li Y; Anand-Srivastava MB
Biochem J; 2000 Mar; 346 Pt 2(Pt 2):313-20. PubMed ID: 10677348
[TBL] [Abstract][Full Text] [Related]
5. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells.
Chen HW; Huang HC
Br J Pharmacol; 1998 Jul; 124(6):1029-40. PubMed ID: 9720770
[TBL] [Abstract][Full Text] [Related]
6. Endothelial exposure to hypoxia induces Egr-1 expression involving PKCalpha-mediated Ras/Raf-1/ERK1/2 pathway.
Lo LW; Cheng JJ; Chiu JJ; Wung BS; Liu YC; Wang DL
J Cell Physiol; 2001 Sep; 188(3):304-12. PubMed ID: 11473356
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells.
Pukac LA; Carter JE; Ottlinger ME; Karnovsky MJ
J Cell Physiol; 1997 Jul; 172(1):69-78. PubMed ID: 9207927
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligodeoxynucleotides downregulated c-sis mRNA expression to inhibit proliferation of vascular smooth muscle cells.
Tang QD; Lin SG; Yu XY
Zhongguo Yao Li Xue Bao; 1999 Jan; 20(1):36-42. PubMed ID: 10437122
[TBL] [Abstract][Full Text] [Related]
9. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.
McPhillips F; Mullen P; Monia BP; Ritchie AA; Dorr FA; Smyth JF; Langdon SP
Br J Cancer; 2001 Nov; 85(11):1753-8. PubMed ID: 11742498
[TBL] [Abstract][Full Text] [Related]
10. Target selectivity of MAPK phosphorothioate antisense ODN on p42/p44, p38 MAPK, and JNK protein expression and its inhibitory effect on VSMC DNA synthesis.
Huang SL; Ding B; Li J; Yi FX; Liu WL; Yu QS; Guo ZG
Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):613-7. PubMed ID: 10678124
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation.
Soldatenkov VA; Dritschilo A; Wang FH; Olah Z; Anderson WB; Kasid U
Cancer J Sci Am; 1997; 3(1):13-20. PubMed ID: 9072302
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA.
Jarvis TC; Alby LJ; Beaudry AA; Wincott FE; Beigelman L; McSwiggen JA; Usman N; Stinchcomb DT
RNA; 1996 May; 2(5):419-28. PubMed ID: 8665409
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effects of PCA-4230, a new antithrombotic drug, in vascular smooth muscle cells.
del Rio M; Sunkel C; Larcher F; Ortega MP
Br J Pharmacol; 1997 Apr; 120(7):1360-6. PubMed ID: 9105713
[TBL] [Abstract][Full Text] [Related]
14. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
Cho YS; Kim MK; Tan L; Srivastava R; Agrawal S; Cho-Chung YS
Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
[TBL] [Abstract][Full Text] [Related]
17. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
18. Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN.
Garl PJ; Wenzlau JM; Walker HA; Whitelock JM; Costell M; Weiser-Evans MC
Circ Res; 2004 Feb; 94(2):175-83. PubMed ID: 14656929
[TBL] [Abstract][Full Text] [Related]
19. Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications.
Schumacher C; Cioffi CL; Sharif H; Haston W; Monia BP; Wennogle L
Mol Pharmacol; 1998 Jan; 53(1):97-104. PubMed ID: 9443936
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
